英语论文
原创论文
留学生作业
英语论文格式
免费论文
essay
英国硕士论文
英国毕业论文
英语论文
留学生论文
澳大利亚论文
新西兰论文
澳洲Report
澳洲留学生论文
美国留学论文
Dissertation
美国硕博论文
essay case
Eassy
Term paper
英语毕业论文
英文论文
课程作业
德语论文
德语专业论文
德语本科论文
德国留学论文
Assignment
日语论文
韩语论文
法语论文
俄语论文

Successful Pregnancy Outcome in Maternal Crigler Najjar Synd

时间:2021-12-12 来源:未知 编辑:梦想论文 阅读:
Abstract: Estimated incidence of Crigler-Najjar syndrome(CNS) is 1 case per 1,000,000 births(1 million). The overall prevalence of CN syndrome is unknown, with only several hundred people reported to have this disease. It is interestingly very rare to encounter a pregnant adult women with congenital jaundice. Pregnancy in CN type II patients is a diagnostic and a therapeutic challenge because of the high risk of bilirubin encephalopathy with serious neurological damage as life-threatening complications for the fetus. To date 8 pregnancy outcome have been reported from 5 women and we report the6 woman with a successful 9 th pregnancy outcome. We have discussed detail history, presentation and management during pregnancy and care of the new born.
 
Keywords: Crigler Najjer Syndrome type II; Unconjugated hyperbilurubinemia; Phenobarbitone; Phototherapy.
 
Introduction
 
Crigler Najjar Syndrome (CNS) is a rare autosomal recessive condition associated with two types in clinical practice. CNS Type I is characterised by complete deficiency and CNS type II by severely reduced activity of hepatic microsomal bilirubin- uridine 5-diphosphate-glucuronosyltransferase (UDPG-T)(1). First case of CNS type I was reported by Crigler and Najjar in 1952 which results in severe unconjugated hyperbilirubinemia and thus neurologic impairment (kernicterus) in the new born, Affected individuals do not respond to Phenobarbital therapy, need prolonged hours of intensive phototherapy, exchange transfusions and, without liver transplantation, usually die in infancy from kernicterus.(1,2) Arias first described CNS Type II, causes milder unconjugated hyperbilirubinemia and responds to phenobarbital treatment and present with episodes of jaundice responding to phenobarbitone.(3-5) The gene coding for UDPG-T, UGT1A1, has been mapped to 2q37 and mutations associated with both type I and type II have been reported.(6-8) Maternal CNS type II is a rare clinical entity with only 8 pregnancies reported from 5 CNS type II pregnant women. We present the 9th pregnancy from 6th woman with CNS type II. Due to paucity of information, we reviewed the literature and with the experience shared by authors,(9-17) were able to have a successful experience through out pregnancy, delivery and the puerperium and we are very grateful to all the authors.
 
Case Report:
 
A 27 year old Gravida 2, para 0, abortion 1, living 0, presented to us at 24 weeks of gestation, with complaints of malaise, low grade fever, yellow discolouration of sclera, high coloured urine. She revealed a past history of first episode of severe jaundice at 5 months of age requiring hospital admission, responded to phototherapy and daily dose of phenobarbitone. Multiple episodes of treatable jaundice were reported. As it is customery in hindu society(tamil origin), women being admitted repeatedly for problems are looked down upon and her mother took the help of ayurvedic practioner, which is indegenious to our country and had noticed alleviation of episodes of jaundice. Husband was also of tamil origin and was unaware of her situation. Following her first abortion 2 years back at 12 weeks of pregnancy associated with sever jaundice, she was investigated at a tertiary centre and produced a stamped referral slip as a case of Crigler Najjar syndrome type II. She responded to phenobarbitone 60 mg/day and 2 years later had a spontaneous conception, with no antenatal care at any medical centre. She looked deeply icteric and dehydrated with 24 weeks of pregnancy. After reviewing the earlier diagnosis and discussing with our gastroenterology collegues we decided to treat her with tablet phenobarbitone 60 mg once a day, maintain hydration and supportive care. Her complete haemogram was normal, anti HIV , anti HbsAg , anti HBC, anti HBE antibodies were negative. She had raised total bilurubin of 13.3 mg/dl, conjugate bilurubin of 0.1 mg/dl, unconjugated bilurubin :13.2 mg/dl. Normal total proteins: 7.4 g/dl, albumin:4.1 mg/dl, normal liver enzymes.blood group was A negative and husband was A positive Ultrasonography of upper abdomen was normal, without any organomegaly. Obstetric scan documented a single live intrauterine pregnancy with fetus in breech, corresponding to dates, normal placenta, liquor volume and no gross congential anomaly. A fetal echo performed was normal. She was kept on follow up every 2 weekly and we plotted her unconjugated bilurubin levels as shown in figure- 1 . at 29 completed weeks she had an episode of premature contractions and so we administered steroids to enhance fetal lung maturity. Her unconjugated bilurubin levels were between 8-9 mg/dl.we continued with phenobarbitone, oral haematenics, calcium, multi vitamin and protein supplements. She went into spontaneous labour at 35-36 weeks of pregnancy and delivered a live male baby weighing 2200 grams, length of baby was 43 centimeters with an APGAR score of 5,6,7,8 at1,5,10,and 15 minutes respectively, length of cord was 34 cms and shifted to neonatal intensive care unit. Neonate had the following Haemoglobin was - 16.9 gm% PCV: 57.3%. reticulocyte count-0.3%, total wbc count - 10,000 cells/mm3 , Platelet count: 1.95 lakh/ mm3 PBS: normocytic and normochromic Blood group and type: A positive. Direct Coombs Test was negative. Total bilurubin- 12.1 mg/dl, direct- 0.6, indirect- 11.5, C-Reactive Protien- 26 mg/litre. Neonatal hyperbilurubinemia table-2 and hypoglycaemia were treated with Intravenous Phenobarbitone. 5 mg/kg body weight 12 hrly and dextrose bolus respectively. By 16 hours of birth baby needed phototherapy as his total bilurubin was stalling. Hence, intensive phototherapy has to be started, total serum bilurubin levels started to decline , by day 5 total Serum bilurubin reached values below 5 mg/dl and declined to reach 3.3 mg/dl and 1.3 mg/dl by day 8 and 14 respectively. Baby was discharged on day 14 .
 
Discussion
 
Crigler-Najjar Syndrome (CNS) is a rare autosomal recessive disorder of bilurubin conjugation as substantiated by many authors.(6-8) Incidence of CNS is probably less than 1 case per 1,000,000 births. Only a few hundred cases have been described in literature and the exact prevalence is unknown (Table-1). Type I presents at birth and is more severe form associated with kernicterus and neurologic morbidity, whereas, type II CNS has late neonatal presentation, lower serum unconjugated bilurubin concentration, which responds to phototherapy and phenobarbital therapy. Due to the rarity of the condition, about 4 pregnancies have been reported in 4 cases of maternal CNS type I and 8 pregnacies from 5 maternal CNS type II (Table-1). With the knowledge we gained by reviewing the literature we realised it would be prudent to start phenobarbital therapy from her past history, rather than debate her genetic basis and perform a liver biopsy which she anyway declined. Gilbert’s syndrome was the other possibility, usualty it presents with hyperbilurubinemai during puberty possibly because of the inhibition of bilirubin glucuronidation by endogenous steroid hormones. Anti HIV, anti HbsAg, anti HBC, anti HBE antibodies were negative ruling out hepatitis, she was not in sepsis as total count was 10,000 cells/mm3 . Her blood group was A Rh typing was negative. We kept her on a close follow up for every two weekly serum total, conjugated and unconjugated bilurubin levels which is depicted in Figure-1.
 
 
Values have ranged from 4.2-10.8 mg/dl, present case it was maintained between 8-9 mg/dl on Phenobarbital therapy 60 mg daily. Similar observations were shared by other authors.(10-13,15,16) Good maternal and fetal outcomes have been reported when, dual treatment consisting of phototherapy during embryogenesis and phenobarbital during the rest of the pregnancy.(15) Though we did not have an opportunity to use phototherapy during the embryogenesis as the patient registered with us at 24 weeks, our maternal and fetal outcomes concur with Ito et al and Holstein et al, Passuello V et al.(11,12,15,16) Rest of the pregnancy and antenatal care was carried out as usual procedure with the fetal anomaly scan, cardiac scan,growth parameter, liquor volume , placental maturity all were correlating with the period of gestation. She had an episode of preterm pain at 29 weeks of gestation and betamethasone 12 miiligrams was given intramuscularly 24 hours apart to enhance lung maturity, to prevent the further burden on immature liver. However, she continued pregnancy and delivered a male baby weighing 2200 grams, length of 43 centimeters at 35-36 weeks of gestation. Baby had initial cyanosis and on bagging and masking the APGAR score improved. But, due to the high risk associated with preterm birth and maternal CNS type II ,baby was immediately transferred to the neonatal intensive care unit. Figure 2 reflects the serial serum total bilurubin levels measured in the baby. At 4 hours and 16 hours of birth total bilurubin levels were 11.5 mg/dl and 11.2 mg/dl even with commencement of f intravenous phenobarbitone 5 mg/kg body weight.hence intensive phototherapy was started at 16 hours of birth. Baby recovered by 8 days and was discharged on request by the parents. Baby had normal developmental miles stones until 1 year of follow up. Similar treatment modalities and nennatal outcomes have been report by some authors.(10-13,15,16) We continued the use of oral Phenobarbital therapy in the mother who later followed up with gastroenterologists. She did not report any puerperial problems.
 
 
Figure:1 Maternal levels of unconjugated bilurubin in mg/dl plotted on the Vertical axis.Horizontal axis depicts pregnancy in weeks, PD-1 week post delivery. Inital values of 13.03 mg/dl has substantially decreased following the start of Phenobarbital therapy- 60 mg/dayred line.
 
 
Figure 2: Neonatal total serum bilurubin levels .Vertical axis –mg/dl and neonatal age in hours after birth on horizontal axis, d- days.
 
We report this case due to its rarity, may be the 6th case of maternal Crigler-Najjar Syndrome Type II who successfully delivered the 9th such baby. When suddenly encountered by such pregnant women with congenital jaundice we were faced with a clinical dielemma, as to are we offering the correct standard of care to optimise the maternal and fetal outcome? This clinical scenario also highlights the importance of basic history taking and consider this condition also in the differential diagnosis of hyperbilurubinemia in pregnancy, which typically has elevated uncongugated bilurubin levels, normal liver enzymes and proteins, may be with an affected member in the family.
 
Data suggest that pregnancy need not be contraindicated in Crigler-Najjar Syndrome Type II. But prompt recognition and interdisciplinary involvement of paediatrician, obstetrician, gastroenterologists, blood bank officer and laboratory technician in these high risk pregnancies we can achieve optimum maternal and fetal outcome( prevent neurologic morbidity and sequale).
 
Acknowledgement:
 
We would like to thank the patient and her family for their ever day to day co-operation. We also thank all the members of Department of Obstetrics, Paediatrics, Gastroenterology, Medicine, Bood bank officials, maternity nurses, Lab technicians and pharmacy members for their valuable inputs. We are grateful to sisters of Good Sheperd convent for all the moral, spiritual and financial support rendered to the patient and her family, without their help we clinicians would not be able to report this case.
 
References
 
1. Tukey RH, Strassburg CP. Human UDPglucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40: 581–616.
2. Crigler JF Jr, Najjar VA: Congenital familial nonhemolytic jaundice with kernicterus; a new clinical entity. AMA Am J Dis Child 1952;83:259–260.
3. Arias M. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J Clin Invest (NY) 1962;41:2233–2245.
4. Gupta R, Parashar Y. Crigler-Najjar syndrome type II. Indian J Pediatr 2004;71:1043.
5. Trotman BW, Shaw L, Roy-Chowdhury J, Malet PF, Rosato EF. Effect of Phenobarbital on serum and biliary parameters in a patient with Crigler-Najjar syndrome, type II and acquired cholestasis. Dig Dis Sci 1983;28:753–762.
6. Costa E. Hematologically important mutations: bilirubin UDPglucuronosyltransferase gene mutations in Gilbert and CriglerNajjar syndromes. Blood Cells Mol Dis2006;36:77–80.
7. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, Jansen PL, Oude Elferink RP. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphateglucuronosyltransferase. J Clin Invest 1994;94:2385–2391.
8. Ritter JK, Yeatman MT, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDPglucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992;90:150–155. 9. Taylor WG, Walkinshaw SA, Farquharson RG, Fisken RA, Gilmore IT: Pregnancy in Crigler-Najjar syndrome. Case report. Br J Obstet Gynaecol 1991;98:1290–1291.
10. Smith JF, Baker JM. Crigler-Najjar disease in pregnancy. Obstet Gynecol 1994;84:670–672.
11. Ito T, Katagiri C, Ikeno S, Takahashi H, Nagata N, Terakawa N. Phenobarbital following phototherapy for Crigler-Najjar syndrome type II with good fetal outcome: a case report. J Obstet Gynaecol Res 2001;27:33–35.
12. Holstein A, Plaschke A, Lohse P, et al. Successful photo- and phenobarbital ther- apy during pregnancy in a woman with Crigler–Najjar syndrome type II. Scand J Gastroenterol 2005;40:1124–1126.
13. Pinkee S, Renu A, Bharati M. Crigler-Najjar syndrome with pregnancy. J Obstet Gynecol India 2005;55:270–271.
14. Holstein A, Bryan CS. Three consecutive pregnancies in a woman with Crigler–Najjar syndrome type II with good maternal and neonatal outcomes. Dig Liver Dis. 2010, doi:10.1016/j.dld.2010.08.003
15. Passuello V, Puhl AG, Wirth S, Steiner E, Skala C, Koelbl H, Kohlschmidt N. Pregnancy Outcome in Maternal Crigler-Najjar Syndrome Type II: A Case Report and Systematic Review of the Literature. Fetal Diagn Ther 2009;26:121–126 DOI: 10.1159/000238122
分享到:
------分隔线----------------------------
发表评论
请自觉遵守互联网相关的政策法规,严禁发布色情、暴力、反动的言论。
最新评论
随机推荐美国留学论文